MB-105 is under clinical development by Mustang Bio and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MB-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MB-105 overview
MB-105 is under development for the treatment of metastatic castration resistant prostate cancer, pancreatic cancer, gastric cancer, and bladder cancer. The therapeutic candidate comprises of autologous T lymphocytes targeting prostate stem cell antigen (PSCA) and CD19 which is done by virus to insert piece of DNA in immune cells. It is developed based on PSCA CAR T technology (PSCA technology).
Mustang Bio overview
Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.
For a complete picture of MB-105’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.